Physician profile
Tim Lekic
NPI 1578855151
$513.91
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $140.28 | 2019 | |
| Emd Serono, INC. | $97.03 | 2019 | |
| Greenwich Biosciences, INC. | $39.55 | 2019 | |
| Jazz Pharmaceuticals INC. | $28.66 | 2019 | |
| Biodelivery Sciences International, INC. | $25.16 | 2019 | |
| Acorda Therapeutics, INC | $25.00 | 2019 | |
| Grifols USA, LLC | $24.33 | 2019 | |
| Akcea Therapeutics, INC. | $20.06 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.19 | 2019 | |
| Scilex Pharmaceuticals INC. | $18.88 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.88 | 2019 | |
| Lundbeck LLC | $16.39 | 2019 | |
| Livanova USA, INC. | $16.02 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.02 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $11.46 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tim Lekic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.